$2.73
(Market cap
$1,127 Mln
Recently Viewed
Clear AllMarket cap
$1,127 Mln
Revenue (TTM)
$16 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1.4
Debt to Equity
2.7
Book Value
$3.5
EPS
$-3.5
Face value
--
Shares outstanding
62,529,408
CFO
$-461.18 Mln
EBITDA
$-590.69 Mln
Net Profit
$-718.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Uniqure NV (QURE)
| -18.7 | 31.7 | -15.5 | 40.4 | 0.1 | -10.6 | 4.2 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Uniqure NV (QURE)
| 35.5 | -70.1 | 9.3 | -42.6 | -49.6 | 148.6 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Uniqure NV (QURE)
|
19.5 | 1,127.4 | 16.1 | -199.0 | -975.8 | -207.1 | -- | 5.7 |
| 4.1 | 1,698.8 | 4.1 | -660.1 | -2,789.5 | -390.4 | -- | 7.6 | |
| 2.1 | 107.0 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 2.2 | |
| 1.6 | 163.3 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 3.0 | |
| 34.1 | 7,824.7 | 2,090.0 | 424.9 | 25.0 | 11.6 | 18.6 | 2.1 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.... Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Read more
CEO & Executive Director
Mr. Matthew Craig Kapusta
CEO & Executive Director
Mr. Matthew Craig Kapusta CPA
Headquarters
Amsterdam
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Uniqure NV (QURE) is $19.46 (NASDAQ) as of 30-Apr-2026 13:38 EDT. Uniqure NV (QURE) has given a return of 0.08% in the last 3 years.
Since, TTM earnings of Uniqure NV (QURE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.92
|
6.92
|
|
2024
|
-3.60
|
-127.74
|
|
2023
|
-1.05
|
1.56
|
|
2022
|
-8.40
|
2.24
|
|
2021
|
2.95
|
1.63
|
The 52-week high and low of Uniqure NV (QURE) are Rs 71.50 and Rs 8.73 as of 30-Apr-2026.
Uniqure NV (QURE) has a market capitalisation of $ 1,127 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Uniqure NV (QURE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.